Sentences with phrase «with a previous study based»

Not exact matches

Based on the GBTA study of 75 countries, here's a look at the top 15 by total business - travel spending in 2012, with percentage growth from the previous year:

About the conversation with TC Campbell, in his China Study audio version, he mentions that he doesn't eat animal based protein, but this only happen a few years previous to the publication of the book.

In a previous study of 24 healthy women, vaginal microbiome composition became less diverse between the second and third trimesters of pregnancy and just before delivery was enriched with Lactobacillus species, likely contributing to vertical transmission of these bacteria during vaginal birth.21 In a study of 10 newborns in Venezuela, within hours of delivery, the intestinal tracts of infants born vaginally were colonized by Lactobacillus and Prevotella, whereas infants delivered operatively acquired bacteria present on the mother's skin and the hospital environment, such as Staphylococcus, Proprionibacterium, and Corynebacterium.15 Quiz Ref ID Our findings, based on a large group of 6 - week - old infants, indicated that Lactobacillus also contributes to the microbial environment of the gut but to a lesser extent than Bifidobacteria, Bacteroides, and Streptococcus.

The team already suspected there might be a link on the basis of previous studies showing that certain antioxidants, such as vitamins C and E, lycophenes or flavonoids, were associated with a reduction in type 2 diabetes risk.

Previous studies have shown that inherited mutations in a gene (called TMLHE) that is required for carnitine biosynthesis are strongly associated with risk for development of autism - spectrum disorders, but the basis for that association has been unclear — until now.

With regard to poor throwing technique, we identified a list of 24 variables that constitute «proper» pitching technique, based on previous studies of several hundred elite professional and college players conducted at ASMI.

Similar approaches have been taken in previous studies using metallic - based superconductors, but with limited success.

«Interestingly, our research showed the use of standing desks improved neurocognitive function, which is consistent with results from previous studies on school - based exercise programs,» Mehta said.

Previous sky surveys with ground - based telescopes have mainly detected giant planets, while NASA's Kepler observatory has uncovered the existence of many smaller exoplanets, but their host stars are faint and difficult to study.

«Compared with several other strains that have been studied, the strain that is least sensitive to the most endocrine - disrupting chemicals has been identified, and the EPA is planning to use it in the screening assays,» says Spearow, now a staff toxicologist for the California EPA; he emphasizes that this is his personal opinion, based on previous work conducted at Davis.

The current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.

The new study, based on recordings from the brains of 37 patients fitted with NeuroPace implants, confirmed previous clinical and research observations of daily cycles in patients» seizure risk, explaining why many patients tend to experience seizures at the same time of day.

Based on results from this and previous studies, pemetrexed and gemcitabine were included in a St. Jude - led multicenter clinical trial of children and adolescents newly diagnosed with medulloblastoma.

Previous genetic studies have examined the association of aspirin, NSAIDs, or both with colorectal cancer according to a limited number of candidate genes or pathways.6 - 10 Thus, to comprehensively identify common genetic markers that characterize individuals who may obtain differential benefit from aspirin and NSAIDs, we conducted a discovery - based, genome - wide analysis of gene × environment interactions between regular use of aspirin, NSAIDs, or both and single - nucleotide polymorphisms (SNPs) in relation to risk of colorectal cancer.

On the basis of the current studies as well as previous reports on the use of intradermal immunization against influenza, hepatitis B, rabies, and other infectious diseases, 2,3,8 it is becoming clear that use of the intradermal route may at least partially overcome the relatively poor influenza - specific immune responses seen in certain at - risk populations, particularly the elderly, in whom the immune response in general is known to diminish with age.9 Moreover, in times of shortage, the dose - sparing intradermal approach might be particularly well suited to the young, healthy persons included in the CDC's high - priority group for vaccination, such as health care workers, as well as to younger, otherwise healthy populations in general.

A multi-step approach, based on previous studies with experimental and simulated data, was used to improve the chance of identifying true heteroplasmies.

«This new study ties in well with previous research into the mental processes that give rise to some of the symptoms of schizophrenia such as paranoia and believing in things that aren't based in reality.

«Previous studies have shown that children with mood and anxiety disorders also have higher rates of autism symptoms, based on the Social Responsiveness Scale,» said senior author Carol Mathews, MD, who did the research while professor of psychiatry at UCSF.

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & AcquisiBased on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

Based on those previous signals, Somaiah and colleagues conducted a phase II study testing the anti — PDL - 1 agent durvalumab in combination with the anti — CTLA - 4 agent tremelimumab in multiple sarcoma subtypes.

While previous studies have looked at the connections between specific defects and the risk of any cancer, or specific cancers and birth defects generally, «what's missing [are] good, population - based estimates of the risk of specific cancers and associations with specific birth defects,» says coauthor Jeremy Schraw, a postdoctoral pediatric cancer researcher at Baylor College of Medicine, during a press conference at AACR.

«Previous studies had identified broader regions of chromosomes that were involved in sexual orientation, but we were able to define these areas down to the base pair level with our approach,» Dr. Ngun said.

The distribution of mutant genes was roughly consistent with expectations based on previous exome - wide sequencing studies of BCs (Cancer Genome Atlas Research Network, 2014).

About the conversation with TC Campbell, in his China Study audio version, he mentions that he doesn't eat animal based protein, but this only happen a few years previous to the publication of the book.

Previous studies in the U.S. have found that a low carbohydrate diet is associated with an increase in overall mortality and showed that when such a diet is from animal - based products, the risk of overall as well as cancer mortality is increased even further (Fung et al., 2010; Lagiou et al., 2007).

Based on previous studies, it was determined that an n of 23 was adequate to defend the 0.05 alpha level of significance with a Cohen probability level of 0.8 (G - Power software, version 3.1.2; Franz Foul, Kiel University, Kiel, Germany).

The resources available will use dyslexia friendly fonts so all students can access the learning - Students will summarise their learning from the previous six topics with some one mark questions and will write down the answers in exercise books Students will review our GCSE studies so far and will see how many topics they have already completed and what also needs to be completed before the May exams Students will be introduced to the key terms of this topic and will answer two tasks based on famous scientists and the relationship they had with religion Students will then answer a task that recognises the differences between scientific truth and religious truth and will finish with some two mark questions from the two previous theme topics

The resources available will use dyslexia friendly fonts so all students can access the learning - Students will summarise our learning from the previous six topics with some one mark questions and will write down the answers in your exercise books Students will then recall the differences between science and religion on the origins of the universe and life and will make a list of three differences between science and religion Students will study and research the different interpretations in Christianity of the Genesis creation story and will answer four tasks based on research about these different interpretations Students will study the role that science and religion play in people's lives and will make a list of things that attract people to science over religion Students will make a list of things that make people religious and will then plan for a potential 12 mark question

Although previous research has emphasized the difficulty teachers have in employing such reforms - based instruction (e.g., Johnson, 2006; Gess - Newsome, 2003; Loucks - Horsley et al., 1998), we often observed the participants in this study using the IDS to implement instructional approaches consistent with current science education reform documents.

The «given» includes students» cultural and language - based contexts, their biases (for example, from previous successes or failures with learning about the subject), and the relevant factual and conceptual knowledge that they have gained from daily experience and formal study.

We did not associate runs of homozygosity in English bulldogs with characteristic phenotypic traits but are confident based on previous studies that the greater genomic variation in English bulldogs compared to Standard Poodles reflected stronger human - directed selection in the former breed than in the latter.

This also goes against the idea of scientists» opinions being entirely based on objective analysis of the evidence, and concurs with previous studies that have shown scientists» opinions on topics to vary along with their political orientation,» writes survey author Neil Stenhouse of George Mason University.

The results of this model - based study fall in line with the previous work of Idso (2013), who calculated similar CO2 - induced benefits on global crop production by mid-century based on real - world experimental data, both of which studies reveal that policy prescriptions designed to limit the upward trajectory of atmospheric CO2 concentrations can have very real, and potentially serious, repercussions for global food security.

Although several different algorithms have been used to derive sea ice concentrations from the satellite measurements, our analyses based on the Hurrell et al. (2008) data are consistent with previous studies.

This also goes against the idea of scientists» opinions being entirely based on objective analysis of the evidence and concurs with previous studies that have shown scientists» opinions on topics to vary along with their political orientation (Nisbet 2011; Rosenberg et al. 2010).

As compared with previous studies that have suggested shared mobility services complement transit services, we find that the substitutive versus complementary nature of ride - hailing varies greatly based on the type of transit service in question.

The sample size estimation was based on a previous study indicating that, to detect a medium effect size of Cohen's d = 0.5, a sample of 128 children (IG, n = 64; CG, n = 64) was required27 at 80 % power and with α set at P <.05.

The SMFQ is a valid instrument48 with adequate psychometric properties, 49 and a previous study based on the youth@hordaland study found the SMFQ to be unidimensional, supporting the use of the sum score of SMFQ.50 Reliability in the current sample was excellent (range = 0 — 26, ordinal α = 0.95).

There is growing evidence for online mindfulness courses being as effective as other face - to - face interventions and online courses for stress even without a therapeutic alliance.37 — 40 Previously found Perceived Stress Scale (PSS) effect sizes are comparable to those found with face - to - face mindfulness and CBT interventions, including our previous research examining the course currently under investigation.40 — 42 One RCT found that an automated internet - based therapy including CBT and mindfulness actually had better outcomes for Irritable Bowel Syndrome (IBS) than the comparative online therapist - led intervention, suggesting that the effects of internet interventions can not be attributed to, and do not rely on, therapist interaction.43 Studies are finding that online mindfulness courses can be beneficial for depression in samples with IBS and epilepsy and anxiety symptoms in a non-clinical sample comparing a 3 - week mindfulness course with positive psychology interventions and treatment as usual (see Monshat38 for a review).

Childhood ADHD may be a risk factor for later criminal behavior.5, 23 — 26 Previous research also suggests that ADHD may be associated with increased mortality, particularly from suicide or accidents.23 We have previously described risk factors for ADHD, childhood comorbidities, treatment history, and educational outcomes through age 19 years for this cohort of ADHD cases.27 — 32 However, no study to date has reported mortality rates in a population - based cohort of childhood ADHD cases followed into adulthood.

This finding is consistent with recent data highlighting the difficulty of reducing suicidal thoughts and behaviors among adolescents.42 We are unaware of any prior epidemiologic data on the lifetime treatment of suicidal adolescents, so there is no basis for comparison of our findings with those of previous studies.

Based on theories and previous studies on online communication, we proposed two hypotheses to better under - stand the effects of online communication on subjective well - being with a sample of Chinese adolescents (n = 190).

Parents were assessed with the Family Schedule for Affective Disorders and Schizophrenia.19 Teens were grouped into clinical groups based on their depressive symptoms and determination of DSM - III - R20, 21 diagnoses; details on all interviewed subjects are reported elsewhere.22 This analysis focuses on a medium depression group (n = 123 [25.9 %]-RRB-, which was called the subsyndromal group.12 These teens reported a previous depression episode or subdiagnostic levels of depressive symptoms that were insufficient to meet full criteria for a DSM - III - R affective diagnosis (Center for Epidemiologic Studies Depression Scale score, ≥ 24).16 Teens who met the criteria for the subsyndromal group and agreed to participate were randomized to receive either the prevention intervention program or usual care.

Cut - off values of 16 and 28 points were used to identify individuals with likely clinical and subclinical anxiety and / or depression, based on previous validation studies in South Africa.

Comparisons of our prevalence rates with those from previous studies are hampered by the fact that there exist few Nordic, population - based studies focusing on men's self - reported exposure to IPV.

However, previous study findings have demonstrated validation for parent - based diagnoses from correlations with teacher and child reports as well as associations with biological findings.24, 27,29,35 Another limitation is the relatively short follow - up period and the fact that the sample was screened and thus not representative.

This screening procedure for outliers was based on previous studies conducted with children (Waters et al., 2012).

To assess the influence of widowhood within each sex, we considered the possible covariates of depressive symptoms identified by the results of previous population - based studies, including age, education, income, experience with chronic diseases, disability, number of children, and social participation.

Cohabiting couples who have a child in their twenties and then break up — and that's almost two - fifths of them in the first five years — often also go on to have another partner or partners.44 One study of young urban parents based on data from the Fragile Families and Child Wellbeing Study found that for 59 percent of unmarried couples with a baby, at least one partner already had a child from a previous relationstudy of young urban parents based on data from the Fragile Families and Child Wellbeing Study found that for 59 percent of unmarried couples with a baby, at least one partner already had a child from a previous relationStudy found that for 59 percent of unmarried couples with a baby, at least one partner already had a child from a previous relationship.

Although the results from previous studies investigating mindfulness - based programs for children with ASD, their parents, or both are promising, further research is required to investigate whether these preliminary effects can be supported and extended to larger samples, younger age groups, and long - term effectiveness.